Role of Advanced Glycation End Products on Aortic Calcification in Patients with Type 2 Diabetes Mellitus

Pilar Sanchis 1,2,*, Rosmeri Rivera 2, Regina Fortuny 3, Carlos Rio 4, Miguel Mas-Gelabert 5, Marta Gonzalez-Freire 2, Felix Grases 1 and Luis Masmiquel 2,*

1 Laboratory of Renal Lithiasis Research, Dept of Chemistry, University of Balearic Islands, Institute of Health Sciences Research [IUNICS-IdISBa], 07122 Palma of Mallorca, Spain. CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN). Instituto de Salud Carlos III, Madrid, Spain.
2 Vascular and Metabolic Diseases Research Group, Endocrinology Department, Son Llàtzer University Hospital, Institute of Health Sciences Research [IdISBa], 07198, Palma of Mallorca, Spain.
3 Laboratory Department, Son Llàtzer University Hospital, 07198, Palma of Mallorca, Spain.
4 Proteomics department, Institute of Health Sciences Research of Balearic Islands (IdISBa), 07120, Palma of Mallorca, Spain.
5 Radiology Department, Son Llàtzer University Hospital, 07198, Palma of Mallorca, Spain.
* Corresponding author.
P.S and R.R. shares first-authorship.

Abstract: The aim of this study was to evaluate the relationship between serum levels of advanced glycation end products (AGEs) and abdominal aortic calcification (AAC) in patients with type 2 diabetes mellitus (DM2). This was a prospective cross-sectional study conducted from January 2017 to June 2018. One-hundred and four consecutive patients with DM2 were given lateral lumbar X-rays in order to quantify aortic abdominal calcification AAC. Circulating levels of AGEs and classical cardiovascular risk factors were determined. Clinical history was also registered. Patients with higher AGEs values had higher grades of aortic calcification and higher number of diabetic related complications. Multivariate logistic regression analysis showed that being older, male and having high levels of AGEs and triglycerides were the independent risk factors associated to moderate-severe AAC when compared to no-mild AAC. Our results suggest that AGEs plays a role in the pathogenesis of aortic calcifications. In addition, the measurement of AGEs levels may be useful for assessing the severity of AAC in the setting of diabetic complications.

Keywords: AGEs; aortic calcification; type 2 diabetes mellitus; diabetes-related complications

1. Introduction

Cardiovascular (CV) disease is the leading cause of death in patients with type 2 diabetes mellitus (DM2) in Western countries and represents a major burden on morbidity, quality of life and health resources. Thus, the identification of patients with DM2 at a high risk of a CV event is important to develop early interventions and prevention strategies. In clinical practice, patients with worse lipid profiles, higher blood pressure, obesity, hyperglycemia, cardiac hypertrophy or dysfunction, nephropathy, neuropathy and/or retinopathy tend to have a higher prevalence of CVD [1]. In recent years, however, several studies have suggested that abdominal aortic calcification (AAC) increases the risk of major CV events in patients with DM2 [2-4]. AAC has been related to severe coronary artery calcification and cardiovascular outcomes specially in patients with DM2 and chronic kidney disease [5,6]. Also, it has been reported that AAC predicts major CV events after an acute coronary syndrome and predicts health care costs in older men independent of CV disease status as well [7,8]. Hence, detection and scoring AAC could improve the clinical identification of patients with DM2 at risk of developing major CV events.
AAC is described as the hardening of medial layer of the artery through deposition of hydroxyapatite crystals into the extracellular matrix [9-11]. Calcification occurs, amongst other factors, as a consequence of aging [12], but it can be accelerated by other diseases like renal insufficiency and diabetes [13,14]. Although several factors could accelerate or arrest the natural process of vascular calcification, the pathogenesis of vascular calcification in diabetes is not completely understood. Among the list of inducers, we can find hyperphosphatemia, vitamin D, lipids or inflammatory cytokines, whereas fetuin-A, phytate, pyrophosphate, vitamin K, osteopontin or matrix Gla protein have been described to be inhibitors of vascular calcification [15]. Consequently, further understanding of the mechanisms by which diabetes might favor this process needs to be elucidated. Indeed, high glucose appears to have an important role in the initiation and progression of this complication.

Ideally, AAC can be quantified with computed tomography (CT), lumbar X-ray and dual-energy x-ray absorptiometry (DXA) scans [16]; however, these imaging studies are not routinely performed in clinic. Therefore, circulating biomarkers could be useful to identify those patients more prone to AAC and to develop new treatments. In this regard, LDL, HDL, HbA1c, osteocalcin, phosphate and advanced glycation end products (AGEs) have been identified as potential markers of AAC but literature is ambiguous and further research is needed [2].

AGEs are the irreversible products of the reaction between amino groups of proteins and sugar resulting from long-term hyperglycemia [17]. AGEs are formed at an accelerate rate under non-controlled diabetic state and play an important role to the development and progression of vascular complications in diabetes [18]. AGEs can affect cell function via intracellular glycation of proteins [19], provoke arterial stiffness by cross-linking of extracellular matrix proteins in arteries [20], and induce receptor-mediated cell activation by binding to the receptor of AGEs (RAGE) [21]. AGEs are believed to be involved in the onset and progression of atherosclerosis through multiple mechanisms and several studies indicate that AGEs and their receptors (RAGEs) play an important role in vascular calcification [22]. In individuals with chronic kidney disease (CKD), AGEs have been associated with arterial calcification [23,24]. Recently, several studies using different models of vascular smooth muscle cells (VSMC) demonstrated the implication of AGEs in calcification [25-28]. Indeed, it was shown that exposure of VSMC to AGEs induced cell calcification [29]. However large studies investigating plasma AGEs levels and their relation with AAC are scarce.

Therefore, the main objectives of the present study are: 1) To examine the association between serum levels of AGEs with AAC, quantified on lumbar X-ray. 2) To determine the most important CV risk factors and diabetic complications associated to moderate-severe AAC in T2DM.

2. Experimental Section
2.1. Subjects and Methods
104 patients with DM2 were recruited consecutively at the Outpatient Diabetic Clinic of Son Llàtzer University Hospital (Palma de Mallorca, Spain). The demographic characteristics of the patients according to the AGEs levels are shown in Table 1. Briefly, patients were included if they were older than 40 years, had DM2 duration longer than 1 year, and had a lumbar X-ray performed in the past 6 months. Exclusion criteria were: life expectancy shorter than 1 year, immunodeficiency, HIV infection, drug abuse or alcohol intake higher than 50 g/day, BMI higher than 40 Kg/m2, participation in a clinical trial in the past year, inability to attend programmed visits, illiteracy, chronic or acute infection in the past 3 months, neoplasia in the past 5 years, vasculitis, resistant hypertension, moderate or severe hepatic insufficiency or glomerular filtration rate (GFR) lower than 30 mL/min/1.73 m2.
The study protocol was approved by the Ethics Committee of the Balearic Islands (Approval number: CEIC-IB 2523/15PI). Written informed consent was obtained from all study participants.

2.2. Variables outcomes

The main outcome measures were serum level of AGEs and AAC scores. Clinical histories were obtained from the electronic medical records. Furthermore, data from anamnesis, laboratory analysis, and physical examinations were prospectively collected during the study. Physical and anthropometric measurements were determined by qualified personnel. Blood samples were collected in the morning (after 12 h of fasting). The samples were left to stand for 30 min at room temperature, and the serum was then separated by centrifugation. Biochemical analyses were performed in an automated analyzer (Cell-Dyn Sapphire and Architect ci16200, Abbott). Insulin was analyzed by chemiluminescent-immunometric assay (Advia Centaur, Siemens). Highly sensitive C-reactive protein (hs-CRP) and lipoprotein (a) (Lp[a]), were analyzed by Nephelometry (Immage 8000, Beckman Coulter). All samples were run in duplicate, and the coefficients of intra- and inter-assay variation were below 10%.

Blood pressure was measured 3 times consecutively after 5 min of rest while the subject was sitting quietly. The average of the second and third measurements was recorded. Patients using anti-hypertensive drugs and those with systolic blood pressure of 140 mmHg or more and/or diastolic blood pressure of 90 mmHg or more were categorized as having hypertension [30]. Atherosclerosis was diagnosed by having clinically significant carotid and/or femoral plaque burden documented with arterial ultrasonography. Chronic kidney disease (CKD) was diagnosed based on the estimated GFR (stage 2 CKD: 89–60 mL/min/1.73 m2; stage 3a CKD: 59–45 mL/min/1.73 m2; stage 3b: 44–30 mL/min/1.73 m2), calculated as previously described [31].

2.3. Serum AGEs determination

AGEs in serum samples were measured using the Cell Biolabs’ OxiSelect™ AGE Competitive ELISA Kit, which provides rapid detection and quantification of AGE protein adducts. Quantitation was determined by comparing absorbance with that of a known AGE-bovine serum albumin (BSA) standard curve. First, an AGE conjugate was coated on an ELISA plate. The unknown AGE samples or AGE-BSA standards were added to the AGE conjugate pre-absorbed ELISA plate. After a brief incubation, an anti-AGE polyclonal antibody was added, followed by horseradish peroxidase-conjugated secondary antibody. The content of AGE protein adducts in unknown samples was determined by comparison with a pre-determined AGE-BSA standard. The intra-assay coefficient of variation was 6.9% (three replicates for each sample on the same day). The inter-assay coefficient of variation was 9.2% (3 days at the same time).

2.4. Lateral lumbar radiography of abdominal aorta

Lateral lumbar X-rays were performed while patients were standing, using standard radiographic equipment. A minimum of 8 cm of tissue anterior to the lumbar spine, including the abdominal aorta, was visible. The focus-film distance was 100 cm, the tube potential was 94 kV, the tube-current-time product was 33–200 mAs, and the estimated radiation dose was approximately 15 mGy.

ACC was assessed using a previously validated 24-point scale [32,33]. For this 24-point scale, calcified deposits along the anterior and posterior longitudinal walls of the abdominal aorta, adjacent to each lumbar vertebra (L1 to L4), were assessed using the midpoint of the intervertebral space above and below the vertebrae as the boundaries. Calcifications were graded as 0 (no aortic deposits), 1 (small scattered deposits less than one-third the length of the vertebral length), 2 (intermediate quantity of deposits, about one-third or more, but less than two-thirds of the vertebral length), or 3 (extensive deposits of two-thirds or more of the corresponding vertebral length). The scores were determined separately for the anterior and posterior walls; the range was 0 to 6 for each vertebral level, and 0 to 24 for the total.
All subjects were assessed independently by two graders who were blinded to patient data. To validate the X-ray assessment, double readings were performed in all patients demonstrating an excellent inter-observer agreement (intra-class coefficient of correlation R = 0.948, p < 0.0001).

2.5. Statistical Analysis

Data are presented as means and standard deviations, medians and interquartile ranges, or numbers and percentages. Patients were divided in three groups according to tertiles of serum AGEs levels: low (L <6.5 U/mL), intermediate (I: 6.5-10.4 U/mL) and high (H >10.4 U/mL). Intergroup comparisons of serum levels of AGEs employed one-way ANOVA or Kruskal-Wallis test for continuous variables, and the Chi-square test for categorical variables. For the second objective, patients were divided in two groups according the median of AAC scores: no-mild (AAC < 6) and moderate-severe (AAC ≥ 6). Intergroup comparisons of aortic abdominal calcification (AAC) scores employed the independent-samples t-test or the Mann–Whitney U test for continuous variables, and the Chi-square test or Fisher’s exact test for categorical variables. ROC curves of quantitative risk factors associated to moderate-severe AAC were performed. The optimal cutoff values were determined by the maximum Youden index (J), defined as sensitivity + specificity -1. Binary logistic regression models were used to identify risk factors associated to moderate-severe AAC (AAC ≥ 6), with an AAC less than 6 (no-mild AAC) as the reference (odds ratio [OR] = 1). Analysis was performed using the stepwise backward method. A two-tailed p-value less than 0.05 was considered statistically significant. Statistical analyses were performed using SPSS 23.0 (SPSS Inc., Chicago, IL, USA).

3. Results

3.1. Baseline Patients Characteristics

Demographic and clinical characteristics of the three groups are shown in table 1. Patients with higher AGEs levels were older (L: 67.5 ± 7.3; I: 66.9 ± 10.4; H: 73.7 ± 7.9 years; p<0.001) and the percentage of males was also higher (L: 34.3%; I: 50.0% and H: 60.0%; p=0.095), although it did not reach statistical significance. Patients with higher AGEs levels presented more diabetic complications, such as diabetic nephropathy, atherosclerosis and chronic kidney disease (p<0.05). Furthermore, the number of diabetic complications increased with AGEs levels (Figure 1). The percentage of patients with three or more DM complications was 6%, 21% and 34% for low, intermediate and high AGEs groups, respectively (p=0.009) while the percentage of patients with no DM2 complications were 57%, 38% and 23%, respectively. Regarding medication, a higher percentage of patients with high AGEs levels were taking calcium antagonists and antiplatelets when compared to patients with low AGEs levels (p=0.025 and p =0.001, respectively).

3.2. Laboratory analysis parameters

Table 2 shows the clinical and biochemical characteristics for AGEs groups. As can be seen, GFR was lower for High AGEs group compared to Low and Intermediate AGEs groups (L:77.8(55.7-88.9); I:83.1(50.1-98.2);H:65.4(46.0-79.1)ml/min/1.73m²; p=0.040) whereas blood levels of hemoglobin, urea, creatinine, urate, albumin: creatinine ratio and glycated hemoglobin significantly increase with AGEs levels (p<0.05).

3.3. Abdominal Aortic Calcification and AGEs levels

There was a trend toward more AAC as serum AGEs levels increased (figure 2). The median (IQR) of AAC 24-points score was 2(0-5), 9.5(4-13) and 8 (2-13) for low, intermediate and high AGEs groups, respectively (figure 2a, p=0.025). There were 23%, 68% and 63% of patients with moderate-severe AAC in the low, intermediate and high groups respectively (figure 2b, p<0.001). Furthermore, 21 (20.2%) of all patients presented no AAC and of these, 10 (47.6%), 5 (23.8) and 6 (28.6%) presented low, intermediate and high AGEs levels, respectively.
3.4. CV risk factors associated with AAC

Table 3 shows the clinical characteristics and laboratory parameters between patients with no-mild AAC (AAC<6) and moderate-severe AAC (AAC≥6). The group with moderate-severe AAC was older, had a higher percentage of males, more DM2 complications, more prevalence of atherosclerosis, higher percentage of smokers or ex-smokers, lower GFR and higher levels of urinary albumin, albumin:creatinine ratio, creatinine, triglycerides, HbA1c and AGEs compared to those with no-mild AAC.

ROC curves and optimal cut off values were calculated for quantitative risk factors associated to moderate-severe AAC (figure 3). As can be seen, circulating serum AGEs upper than 7 U/mL had a sensitivity and specificity of 81.1% and 56.9%, respectively. The overall accuracy was 68.3% for AGEs upper than 7 U/mL and it was bigger than those for the rest of the analysed variables (62.5% for age upper than 70 years; 61.5% for triglycerides upper than 146 mg/dL; and 64.4% for GFR lower than 74 ml/min/1.73m²).

Univariate and multivariate logistic regression analysis were used to investigate independent factors associated to the presence of moderate-severe AAC (vs. no-mild AAC). All previously listed factors (p<0.05 in table 3) were included initially in the model before stepwise and backward elimination. The final model included age older than 70 years, being male, circulating AGEs levels upper than 7 U/mL, and triglycerides levels upper than 146 mg/dL as the independent risk factors associated to moderate-severe AAC in DM2 (figure 4).
3.5. Figures, Tables and Schemes

Table 1. Clinical characteristics of patients among circulating AGEs groups. Each value is given as mean ± standard deviation or frequency (percentage). The significance of differences between groups were determined using one-way ANOVA or Kruskal-Wallis test for quantitative data and chi-square test for qualitative data.

| Low AGES (<6.5 U/mL) (n = 35) | Intermediate AGES (6.5-10.4 U/mL) (n = 34) | High AGES (>10.4 U/mL) (n = 35) | p-value |
|---------------------------------|---------------------------------|---------------------------------|---------|
| Age (years)                     | 67.5 ± 7.3                      | 66.9 ± 6.9                      | 73.7 ± 7.9 | <0.001 |
| Gender (male)                   | 12 (34.3%)                      | 17 (50.0%)                      | 21 (60.0%) | 0.955  |
| BMI (kg/m2)                     | 31.6 ± 4.8                      | 31.1 ± 4.4                      | 31.4 ± 8.1 | 0.689  |
| Waist circumference (cm)        | 110 ± 10                        | 110 ± 11                        | 108 ± 12  | 0.466  |
| Systolic blood pressure (mmHg)  | 145 ± 17                        | 145 ± 21                        | 147 ± 19  | 0.827  |
| Diastolic blood pressure (mmHg) | 77.4 ± 10.7                     | 76.5 ± 9.8                      | 75.1 ± 12 | 0.827  |
| Pulse pressure (mmHg)           | 67.5 ± 16.1                     | 68.8 ± 17.5                     | 72.3 ± 15.8 | 0.533 |
| Heart rate (pulse/min)          | 78.1 ± 12.6                     | 77.9 ± 13.7                     | 76.4 ± 14.2 | 0.830 |
| Time from diagnosis DM2         |                                 |                                 |          |
| Less than 3 years               | 4 (11.4%)                       | 2 (5.9%)                        | 3 (8.6%)  | 0.726  |
| Between 5 and 10 years          | 10 (28.6%)                      | 11 (32.4%)                      | 7 (20.0%) |         |
| More than 5 years               | 21 (60.0%)                      | 21 (61.8%)                      | 25 (71.4%) |         |

Comorbidities, toxicities and clinical history

| Hypertension                    | 31 (88.6%)                      | 30 (88.2%)                      | 32 (91.4%) | 0.893  |
| Smoking                         | 9 (25.7%)                       | 17 (50.0%)                      | 14 (40.0%) | 0.114  |
| Alcohol                         | 5 (14.3%)                       | 5 (14.7%)                       | 3 (8.6%)  | 0.688  |
| Prior cardiovascular disease    | 15 (42.9%)                      | 13 (38.2%)                      | 20 (57.1%) | 0.258  |
| Chronic kidney disease (CKD)    | 27 (77.1%)                      | 19 (55.9%)                      | 32 (91.4%) | 0.003  |
| 2 (GFR 89-60 ml/min/1.73 m2)    | 17 (48.6%)                      | 9 (26.5%)                       | 17 (48.6%) | 0.045  |
| 3a (GFR 59-45 ml/min/1.73 m2)   | 5 (14.3%)                       | 5 (14.7%)                       | 8 (22.9%) |         |
| 3b (GFR 44-30 ml/min/1.73 m2)   | 5 (14.3%)                       | 5 (14.7%)                       | 7 (20.0%) |         |
| Diabetic retinopathy            | 9 (25.7%)                       | 13 (38.2%)                      | 14 (40.0%) | 0.393  |
| Ischemic heart disease          | 4 (11.4%)                       | 5 (14.7%)                       | 9 (25.7%) | 0.255  |
| Cerebral stroke                 | 3 (8.6%)                        | 3 (8.8%)                        | 8 (22.9%) | 0.135  |
| Diabetic polyneuropathy         | 7 (20.0%)                       | 6 (17.6%)                       | 11 (31.4%) | 0.135  |
| Diabetic foot                   | 1 (2.9%)                        | 1 (2.9%)                        | 3 (8.6%)  | 0.442  |
| Intermittent Claudication       | 2 (5.7%)                        | 2 (5.9%)                        | 6 (17.1%) | 0.207  |
| Atheroscleriosis                | 3 (8.6%)                        | 2 (5.9%)                        | 11 (31.4%) | 0.007  |

Medication use

| Angiotensin-converting enzyme inhibitors / Angiotensin II receptor-blocking agents | 22 (62.9%) | 29 (85.3%) | 24 (68.6%) | 0.19 |
|---------------------------------|---------------------------------|---------------------------------|---------|
| Beta-blockers                   | 13 (37.1%)                      | 9 (26.5%)                       | 14 (40.0%) | 0.462 |
| Calcium antagonists             | 12 (34.3%)                      | 9 (26.5%)                       | 20 (57.1%) | 0.025 |
| Statins                         | 21 (60.0%)                      | 29 (85.3%)                      | 24 (68.6%) | 0.062 |
| Fibrates                        | 2 (5.7%)                        | 1 (2.9%)                        | 2 (5.7%)  | 0.825  |
| Phosphate binders               | 0 (0.0%)                        | 1 (2.9%)                        | 0 (0.0%)  | 0.354  |
| VitD 25 - OH                    | 5 (14.3%)                       | 16 (47.1%)                      | 11 (31.4%) | 0.178 |
| Calcium α Alphacalcidol         | 1 (2.9%)                        | 1 (2.9%)                        | 0 (0.0%)  | 0.596  |
| Paricalcitol                    | 2 (5.7%)                        | 0 (0.0%)                        | 1 (2.9%)  | 0.366  |
| Calcium Supplement              | 4 (11.4%)                       | 3 (8.8%)                        | 3 (8.6%)  | 0.904  |
| Bisphosphonates                 | 3 (8.6%)                        | 0 (0.0%)                        | 2 (5.7%)  | 0.239  |
| Steroids                        | 0 (0.0%)                        | 2 (5.9%)                        | 0 (0.0%)  | 0.123  |
| Antiplatelets                   | 13 (37.1%)                      | 27 (79.4%)                      | 22 (62.9%) | 0.001 |
| Oral anticoagulants             | 4 (11.4%)                       | 3 (8.8%)                        | 5 (14.3%) | 0.777  |
| Insulin                         | 19 (54.3%)                      | 17 (50.0%)                      | 20 (57.1%) | 0.836 |
| Oral antidiabetic               | 30 (85.7%)                      | 30 (88.2%)                      | 26 (74.3%) | 0.262 |
| Uric acid medication (allopurinol or febuxostat) | 5 (14.3%) | 5 (14.7%) | 8 (22.9%) | 0.566 |
| Potassium citrate               | 0 (0.0%)                        | 0 (0.0%)                        | 1 (2.9%)  | 0.37   |
| Thiazides                       | 10 (28.6%)                      | 10 (29.4%)                      | 12 (34.3%) | 0.856 |
| Furosemide or triamterene       | 8 (22.9%)                       | 9 (26.5%)                       | 11 (31.4%) | 0.719 |
| Spironolactone or eplerenone    | 1 (2.9%)                        | 2 (5.9%)                        | 3 (8.6%)  | 0.591  |
Figure 1. Diabetic related-complications among serum AGEs levels. The significance of differences between groups were determined using chi-square test (p=0.009).

Table 2. Laboratory parameters among AGEs groups. Each value is given as median (interquartile range). The significance of differences between groups were determined using one-way ANOVA or Kruskal-Wallis test.
Figure 2. AAC score (a) and percentage of patient with no-mild AAC and moderate-severe AAC (b) among AGEs levels in patients with DM2. The significance of differences between groups were determined using or Kruskal-Wallis and Mann-Whitney U test for (a) and chi-square test for (b). * p<0.05 vs low serum levels of AGEs (<6.5 U/mL).
**Table 3.** Clinical characteristics and laboratory parameters between patients with no-mild AAC and moderate-severe AAC. Each value is given as mean (± standard deviation), frequency (percentage) or median (interquartile range). The significance of differences between groups were determined using independent t-test or Mann-Whitney U test for quantitative data and chi-square test or Fisher's exact test for qualitative data.

| Comorbidities, toxics and clinical history | No-Mild AAC (AAC < 6) (n=51) | Moderate-Severe AAC (AAC ≥ 6) (n=53) | p-value |
|------------------------------------------|-----------------------------|-----------------------------------|---------|
| Chronic Kidney disease (stage 2 or upper) | 34 (66.7%) | 44 (86.3%) | 0.071 |
| Hypertension | 45 (88.2%) | 48 (94.1%) | 0.758 |
| Smoking (current or ex) | 13 (25.5%) | 27 (52.9%) | 0.009 |
| Alcohol (current or ex) | 8 (15.7%) | 5 (9.8%) | 0.386 |
| Prior cardiovascular disease | 20 (39.2%) | 28 (54.9%) | 0.175 |
| Diabetic retinopathy | 15 (29.4%) | 21 (39.6%) | 0.308 |
| Ischemic heart disease | 5 (9.8%) | 13 (24.5%) | 0.069 |
| Cerebral stroke | 5 (9.8%) | 9 (17.0%) | 0.391 |
| Diabetic polyneuropathy | 9 (17.6%) | 15 (28.3%) | 0.247 |
| Diabetic foot | 1 (2.0%) | 4 (7.5%) | 0.363 |
| Intermittent claudication | 2 (3.9%) | 8 (15.1%) | 0.930 |
| Atherosclerosis | 3 (5.9%) | 13 (24.5%) | 0.013 |

**Laboratory parameters**

| Parameter | No-Mild AAC | Moderate-Severe AAC | p-value |
|-----------|-------------|---------------------|---------|
| AGES (U/mL) | 5.9 (4.5 - 10.1) | 9.7 (7.5 - 11.1) | 0.015 |
| HbA1c NGSP/DCCT (%) | 7.2 (6.4 - 8.1) | 7.4 (6.9 - 8.4) | 0.171 |
| Leukocytes (x109/L) | 7.8 (6.7 - 9.3) | 7.5 (6.3 - 9.3) | 0.509 |
| Hemoglobin (g/dL) | 13.4 (12.5 - 14.5) | 13.0 (11.6 - 14.5) | 0.164 |
| Glucose (mg/dL) | 152 (125 - 180) | 139 (111 - 226) | 0.701 |
| Creatinine (mg/dL) | 0.8 (0.7 - 1.1) | 1.1 (0.8 - 1.4) | 0.004 |
| Urate (mg/dL) | 5.2 (4.5 - 6.0) | 6.2 (4.3 - 7.3) | 0.036 |
| Sodium (mg/L) | 140 (139 - 141) | 140 (138 - 142) | 0.536 |
| Potassium (mg/L) | 4.4 (4.2 - 4.7) | 4.7 (4.3 - 5.0) | 0.022 |
| Calcium (mg/dL) | 9.5 (9.2 - 9.8) | 9.4 (9.2 - 9.7) | 0.577 |
| Phosphate (mg/dL) | 3.5 (3.2 - 3.8) | 3.4 (3.1 - 3.8) | 0.320 |
| Total Cholesterol (mg/dL) | 158 (134 - 180) | 154 (141 - 177) | 0.964 |
| HDL Cholesterol (mg/dL) | 42.5 (36.0 - 49.0) | 38.0 (32.0 - 47.5) | 0.199 |
| LDL Cholesterol mg/dL | 93.0 (68.3 - 105.2) | 85.0 (67.8 - 100.9) | 0.599 |
| Triglycerides (mg/dL) | 121 (94 - 176) | 149 (103 - 203) | 0.048 |
| Albumin (g/dL) | 4.2 (4.0 - 4.4) | 4.0 (3.8 - 4.2) | 0.004 |
| Alkaline Phosphatase (u/L) | 77 (57 - 91) | 82 (67 - 93) | 0.356 |
| PTHi (pg/mL) | 67.0 (48.9 - 94.6) | 74.2 (51.8 - 102.9) | 0.333 |
| 25 OH Vit D3(ng/ml) | 23.0 (16.3 - 41.0) | 26.8 (18.0 - 34.0) | 0.547 |
| GFR (ml/min/1.73m2) | 79.2 (57.4 - 95.3) | 68.0 (47.1 - 82.3) | 0.024 |
| Urinary Creatinine (mg/dL) | 70.5 (52.4 - 89.7) | 60.3 (39.2 - 89.7) | 0.184 |
| Urinary Alb/creatinine ratio (mg/g) | 10.9 (5 - 29) | 25 (9 - 149) | 0.004 |
| Urinary albumin (mg/dL) | 0.6 (0.5 - 3.6) | 1.1 (0.5 - 17.1) | 0.012 |

doi:10.20944/preprints202005.0341.v1
Figure 3. ROC curves and optimal cut-off of quantitative risk factors associated to moderate-severe AAC (vs. no-mild AAC). The optimal cutoff values were determined by the maximum Youden index (J), defined as sensitivity + specificity -1. The table indicate the area under the curve (AUC), sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and overall accuracy of the optimal cut off values.
Figure 4. Forest plot and ROC curve of the multivariate logistic regression of risk factors associated to moderate-severe AAC in patients with DM2. Multivariate analysis was performed using stepwise backward method. Crude and adjusted Odds Ratio (O.R.) are indicated in the table. Comparison of the expected and observed frequencies by the Hosmer-Lemeshow goodness-of-fit test ($p$-value = 0.734) and by ROC curve (AUC = 0.802; $p$<0.001) indicated a good fit for the model.

4. Discussion

Our study reports that serum levels of a pool of circulating AGEs determined by ELISA positively correlated with AAC (based on lateral lumbar X-rays) in subjects with DM2. Previously, Saremi et al. prospectively demonstrated in the VA Diabetes Trial and Follow-up Study that baseline plasma levels of N-carboxyethyl lysine (CEL) determined by liquid chromatography-mass spectrometry were strongly associated with the extend of AAC determined by CT-scanning after an average of 10 years of follow-up [34]. However, this study did not report AGE measurements at the time of CT acquisition, so the relationship between AGE and AAC at the same time-point was not examined.

Secondly, we have also observed that both groups of patients with intermediate and high AGEs levels had a higher prevalence of diabetes-related complications. Several data have linked circulating AGEs to the development and progression of diabetes complications [35-37] including diabetic retinopathy [38-41], nephropathy [42,43], and cardiovascular disease [44-46]. Furthermore, an accumulation of AGEs has been detected in most of target tissues of diabetes complications, such as
the kidney, retina, and atherosclerotic plaques [47]. Several studies have shown correlations between serum levels of AGEs and the development/severity of vascular disease [48-52].

Our results indicate that circulating levels of AGEs are mainly correlated with CKD and aging. These results are consistent with previous studies which found that serum AGEs are positively correlated with serum creatinine and an inversely correlated with GFR [23,24, 35,42,53]. Regarding aging and circulating levels of AGEs, our results are in accordance with other authors who indicated that AGEs are linked to the aging process [35,36,47,51,54,55] and are considered a marker of senescence [56].

On the other hand, we find an association between circulating AGEs and HbA1c. Similar results have been found in other studies [35] where AGEs levels were higher in patients with poor glycemic control measured by HbA1c [54, 57-59]. It is important to consider that the extent and duration of hyperglycemia are predicted by increased levels of HbA1c, which is considered an acceptable marker. As mentioned above, prolonged exposure to glucose produces early AGEs and affects different proteins. An important example of early glycated proteins is HbA1c, which is further modified through a series of reactions in Hb-AGE. Under normal conditions, Hb-AGE makes up 0.42% of circulating hemoglobin (Hb) levels, increasing to 0.75% in diabetic subjects [60]. Besides HbA1c correlates with AGEs, AGEs-modified proteins are hardly degraded and remain in the vessels, kidney and heart for a long time, even after glycemic control has improved. Therefore, AGEs are considered to be a better index of cumulative diabetic exposure and one of the main actors of the metabolic memory observed in diabetic patients.

Concerning to the factors associated to AAC, our results show that moderate-severe AAC is associated to current or ex tobacco use. Similar results were found in other studies, where cigarette smoking was strongly associated with calcification [61]. The independent factors however associated with AAC in our patients were age, male gender, AGEs levels and plasma triglycerides. These results are in accordance with previous studies which have reported that age and prior CV disease are strongly associated with AAC [62-64]. Triglycerides can be markers of glycemic control and have become an independent predictor of cardiovascular risk, as demonstrated by multiple prospective epidemiological studies [65-68]. Also, it is well-known that vascular calcification is more common in males than in females [69]. It is worth to underline that we developed ROC curves and searched the optimal cut-off values associated to AAC. Remarkably, the accuracy for AGEs was higher than the observed for the other factors classically related to AAC (figure 4). Moreover, an AUC higher than 0.8 showed a good fit for the multivariate model of factors associated to moderate-severe AAC (figure 4).

Our results support the notion that AGEs can play a role in the pathogenesis of aortic calcifications and are in accordance with tissue culture studies that indicate that AGEs can act as inducer of calcification affecting cell function via both, intracellular glycation of proteins and AGE-RAGE signaling [20,22,70].

Considering that morbidity and mortality in patients with DM2 are mainly due to cardiovascular disease, the measurement of circulating AGEs could be useful as an early marker of the presence and severity of AAC and the occurrence of future diabetic complications. In addition, an inhibitory therapy of the formation of AGEs or a therapy addressed against AGE-RAGE system could be useful as a preventive treatment in the development of AAC and diabetic complications. Recently, DNA aptamers directed against AGE and RAGE, attenuating their interaction, have been developed and are being studied with promising experimental results [71]. Also, phytate has been described to inhibit glycation processes by iron chelation process [72] and it is a well-known inhibitor of AAC via absorption over the hydroxyapatite crystals. Consequently, it is possible that this compound can be a strong inhibitor of the formation of AAC via the two mentioned mechanisms [73-75]. Interestingly, a recent study suggests that the antidiabetic therapy with a sodium-glucose cotransporter inhibitor could reduce the levels of AGEs in comparison with a dipeptidyl peptidase-4 inhibitor [76]. Finally, beside drugs or compounds, avoid smoking and restriction of dietary AGEs consumption must be taken in mind to reduce AGEs burden [77,78].
Our study has several limitations. First, the sample is small and it is a cross-sectional study from a single medical center, therefore the findings presented here should be interpreted with caution. Even though we found that age, gender, triglycerides and circulating levels of AGEs were associated to AAC, this does not prove causality. Prospective multicentric longitudinal studies are needed to fully clarify how AGEs actually contribute to the genesis and progression of AAC and to assess the possibility that circulating levels of AGEs may serve as biomarkers to predict or diagnose AAC. Other possible limitation is that we measured AAC using lateral abdominal plain X-rays. One could argue that CT is more sensitive. Several studies however have positioned lateral lumbar radiography as a tool to estimate the severity of AAC. Furthermore, AAC evaluated by lateral X-ray shows a good correlation with coronary calcium score [4,79]. Therefore, we consider that plain radiography is an appropriate screening method for evaluating AAC in daily practice since it is simpler, cheaper and with lesser radiation than CT.

Finally, there are several methods available to measure AGEs and there are no single standardized protocols or normal reference ranges established for them. We measured a pool of AGEs by ELISA. It has been observed that CEL but not methylglyoxal hydroimidazolone, 3-deoxyglucosone hydroimidazolone, 2-aminoadipic acid and methionine sulfoxide was related to AAC [34]. Therefore, it is possible that our results were related to specific AGEs. Thus, further studies aimed at addressing these issues are needed.

5. Conclusions

In conclusion, we provide evidence that serum levels of AGEs positively correlate with AAC in patients with DM2. In addition, our study suggests that age, gender, triglycerides and circulating levels of AGEs are the risk factors associated to moderate-severe AAC. We also have shown that circulating levels of AGEs were positively associated with AAC severity and diabetes-related complications. Therefore, increased levels of AGEs can be contemplated as a biomarker of AAC and other vascular complications of diabetes.

Author Contributions: All authors make substantial contributions to conception and design, and/or acquisition of data, and/or analysis and interpretation of data: conceptualization, P.S., LM and FG; methodology, P.S., RR, M.M.-G. and LM; software, M.M.-G., P.S. and RR; validation, P.S., RR. and LM.; formal analysis, P.S and RR.; investigation and resources, RR., P.S., R.F., M.G.-F., M.M. and C.R.; data curation, RR., and P.S.; writing-original draft preparation, P.S., RR. and LM.; writing-review and editing L.M., FG. RR., M.G.-F. and P.S.; visualization, LM, RR. and P.S.; supervision, L.M., F.G. and P.S.; project administration L.M., F.G. and P.S.; funding acquisition, L.M., F.G. and P.S. All authors have read and agreed to the published version of the manuscript.

Aknowledgements: MGF acknowledges funding by the Miguel Servet Program (MS19/00201), Instituto de Salud Carlos III (ISCIII), Madrid.

Funding: This research was funded by Balearic Islands Government, grant number AAEE033/2017.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Cosentino, F.; Grant, P.J.; Aboyans, V.; Bailey, C.J.; Ceriello, A.; Delgado, V.; Federici, M.; Filippatos, G.; Grobbbee, D.E.; Hansen, T.B.; Huikuri, H.V.; Johansson, I.; Jüni, P.; Lettino, M.; Marx, N.; Mellbin, L.G.; Östgren, C.J.; Rocca, B.; Roffi, M.; Sattar, N.; Seferović, P.M.; Sousa-Uva, M.; Valensi, P.; Wheeler, D.C.; ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020; 41: 255-325. doi: 10.1093/eurheartj/ehz486.

2. Bendix, E.F.; Johansen, E.; Ringgaard, T.; Wolder, M.; Starup-Linde, J. Diabetes and Abdominal Aortic Calcification-a Systematic Review. Curr Osteoporos Rep 2018; 16; 42-57. doi: 10.1007/s11914-018-0418-z.

3. Kalofoutis, C.; Piperi, C.; Kalofoutis, A.; Harris, F.; Phoenix, D.; Singh, J. Type II diabetes mellitus and cardiovascular risk factors: current therapeutic approaches. Exp Clin Cardiol 2007; 12; 17–28.
4. Bastos-Goncalves, F.; Voute, M.T.; Hoeks, S.E.; Chonchol, M.B.; Boersma, E.E.; Stolker, R.J.; Verhagen, H.J.M. Calcification of the abdominal aorta as an independent predictor of cardiovascular events: a meta-analysis. Heart 2012; 98: 988–94. doi: 10.1136/heartjn1-2011-301464.

5. Cho, A.; Jung, H.Y.; Park, H.C.; Oh, J.; Kim, J.; Lee, Y.K. Relationship between abdominal aortic calcification on plain radiography and coronary artery calcification detected by computed tomography in hemodialysis patients. Clin Nephrol 2020; 93: 123-129. doi: 10.5414/CN109988.

6. Zhu, X.; Cai, H.; Zhu, M.; Zhan, Y.; Che, M.; Lin, X.; Zhang, W.; Ni, Z. Association of abdominal aortic calcification estimated by plain radiography with outcomes in hemodialysis patients: A 6-year follow-up study. Nephrology (Carlton) 2019; online ahead of print; doi: 10.1111/nep.13644.

7. Oishi, H.; Horibe, H.; Yamase, Y.; Ueyama, C.; Takemoto, Y.; Shigeta, T.; Hibino, T.; Kondo, T.; Suzuki, S.; Ishii, H.; Murohara, T. Predictive value of abdominal aortic calcification index for mid-term cardiovascular events in patients with acute coronary syndrome heart vessels. Heart Vessels 2020; 35; 620-9. doi: 10.1007/s00380-019-01527-6.

8. Schousboe JT, Vo TN, Langsetmo L, Adlabag S, Szulc P, Lewis JR, Kats AM, Taylor BC, Ensrud KE. Abdominal Aortic Calcification (AAC) and Ankle-Brachial Index (ABI) Predict Health Care Costs and Utilization in Older Men; Independent of Prevalent Cardiovascular Disease and Each Other. Atherosclerosis 2020; 295; 31-7. doi: 10.1016/j.atherosclerosis.2020.01.012.

9. Giachelli, C.M. Vascular calcification mechanisms. J Am Soc Nephrol 2004; 15; 2959-64. doi: 10.1077/01.ASN.000145894.57533.C4.

10. Wu, M.; Remeter, C.; Giachelli, C.M. Vascular calcification: an update on mechanisms and challenges in treatment. Calcif Tissue Int 2013; 93; 365–373. doi: 10.1007/s00223-013-9712-z.

11. Demer, L.L.; Tintut, Y. Vascular calcification: pathobiology of a multifaceted disease. Circulation 2008; 117; 2938-48. doi: 10.1161/CIRCULATIONAHA.107.743161.

12. Pescatore, L.A.; Gamarra, L.F.; Liberman, M. Multifaceted mechanisms of vascular calcification in aging. Arterioscler Thromb Vasc Biol 2019; 39; 1307-16. doi: 10.1161/ATVBAHA.118.311576.

13. Harper, E.; Forde, H.; Davenport, C.; Rochfort, K.D.; Smith, D.; Cummins, P.M. Vascular calcification in type 2 diabetes and cardiovascular disease: Integrative roles for OPG; RANKL and TRAIL. Vasc Pharmacol 2016; 82; 30-40. doi: 10.1016/j.vph.2016.02.003.

14. Schlieper, G.; Schurgers, L.; Brandenburg, V.; Reutelingsperger, C.; Floege, J. Vascular calcification in chronic kidney disease: an update. Nephrol Dial Transplant. 2016; 31; 31-9. doi: 10.1093/ndt/gfv111.

15. Chen, N.X.; Moe, S.M. Pathophysiology of vascular calcification. Curr Osteoporos Rep 2015; 13; 372-80. doi: 10.1007/s11914-015-0293-9.

16. Setiawati, R.; Di Chio, F.; Rahardjo, P.; Nasuto, M.; Dimpudus, F.J.; Guglielmi, G. Quantitative assessment of abdominal aortic calcifications using lateral lumbar radiograph; dual-energy x-ray absorptiometry, and quantitative computed tomography of the spine journal of clinical densitometry. J Clin Densitom 2016; 19; 242-9. doi: 10.1016/j.jocd.2015.01.007.

17. Negre-Salvayre, A.; Salvayre, R.; Augé, N.; Pamplona, R.; Portero-Otín, M. Hyperglycemia and glycation in diabetic complications. Antioxid Redox Signal 2009; 11; 3071-109. doi: 10.1089/ARS.2009.2484.

18. Peppa, M.; Vlassara, H. Advanced glycation end products and diabetic complications: a general overview. Hormones 2005; 4; 28-37. DOI: 10.14310/horm.2002.11140.

19. Brownlee, M. Advanced protein glycosylation in diabetes and aging. Annu Rev Med 1995; 46; 223-34. doi: 10.1146/annurev.med.46.1.223.

20. Aronson, D. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging diabetes. J Hypertens 2003; 21; 3-12. doi: 10.1097/00004872-200301000-00002.

21. Bierhaus, A.; Humpert, P.M.; Stern, D.M.; Arnold, B; Nawroth, P.P. Advanced glycation end product receptor-mediated cellular dysfunction. Ann N Y Acad Sci 2005; 1043; 676-80. doi: 10.1196/annals.1333.077.

22. Kay, A.M.; Simpson, C.L.; Stewart, J.A.Jr. The role of AGE/RAGE signaling in diabetes-mediated vascular calcification. J Diabetes Res 2016; 2016: 6809703. doi: 10.1155/2016/6809703.

23. Taki, K.; Takayama, F.; Tsuruta, Y.; Niwa, T. Oxidative stress, advanced glycation end product, and coronary artery calcification in hemodialysis patients. Kidney Int 2006; 70; 218-24. doi: 10.1038/sj.ki.5000330.

24. NasrAllah, M.M.; El-Shenabary, A.R.; Osman, N.A.; Salem, M.M.; Nassif, A.; Sharaf El Din, U.A.A. Endogenous soluble receptor of advanced glycation end-products (esRAGE) is negatively associated with vascular calcification in non-diabetic hemodialysis patients. Int Urol Nephrol 2012; 44; 1193-9. doi: 10.1007/s11255-011-0067-y
25. Ren, X.; Shao, H.; Wei, Q.; Sun, Z.; Liu, N. Advanced glycation end-products enhance calcification in vascular smooth muscle cells. *J Int Med Res* 2009; 37: 847-54. doi: 10.1177/0300060509330329.

26. Tanikawa, T.; Okada, Y.; Tanikawa, R.; Tanaka, Y. Advanced glycation end products induce calcification of vascular smooth muscle cells through RAGE/p38 MAPK. *J Vasc Res* 2009; 46: 572-80. doi: 10.1159/000226225.

27. Suga, T.; Iso, T.; Shimizu, T.; Tanaka, T.; Yamagishi S; Takeuchi, M.; Imaizumi, T.; Kurabayashi, M. Activation of receptor for advanced glycation end products induces osteogenic differentiation of vascular smooth muscle cells. *J Atheroscler Thromb* 2011; 18: 670-83. doi: 10.5551/jat.7120.

28. Gawdzik, J.; Mathew, L.; Kim, G.; Purì T.S.; Hofmann-Bowman, M.A. Vascular remodeling and arterial calcification are directly, mediated by S100A12 (EN-RAGE) in chronic kidney disease. *Am J Nephrol* 2011; 33: 250-259. doi: 10.1159/000324693.

29. Zhu, Y.; Ma, W.Q.; Han, X.Q.; Wang, Y.; Wang, X.; Liu, N.F. Advanced Glycation End Products Accelerate Calcification in VSMCs Through HIF-1α/PDK4 Activation and Suppress Glucose Metabolism *Sci Rep* 2018; 8; 13730. doi: 10.1038/s41598-018-31877-6.

30. Chobanian, A.V.; Bakris, G.L.; Black, H.R.; Cushman, W.C.; Green, L.A.; Izzo, J.L.Jr.; Jones, D.W.; Materson, B.J.; Oparil, S.; and the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. *Hypertension* 2003; 42: 1206-52. doi: 10.1161/01.HYP.0000107251.4915.c2.

31. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. *Am. J. Kidney Dis.* 2002, 39, 1–266. doi:10.1053/SJkd.2002.30939.

32. Honkanen, E.; Kauppila, L.; Wikstrom, B.; Rensma, P.L.; Krzesinski, J.M.; Aasarod, K.; Verbeke, F.; Jensen, P.B.; Mattelaer, P.; Volck, B.; CORD study group. Abdominal aortic calcification in dialysis patients: results of the CORD study. *Nephrol Dial Transplant.* 2008; 23: 4009-4015. doi: 10.1093/ndt/gfn403.

33. Schoosboe, J.T.; Wilson, K.E.; Hangartner, T.N. Detection of aortic calcification during vertebral fracture assessment (VFA) compared to digital radiography. *PLoS One.* 2007; 2; e715. doi: 10.1371/journal.pone.0000715.

34. Saremi, A.; Howell, S.; Schwenke, D.C.; Bahn, G.; Beisswenger, P.J.; Reaven, P.D.; VADT Investigators. advanced glycation end products, oxidation products; and the extent of atherosclerosis during the VA diabetes trial and follow-up study. *Diabetes Care* 2017; 40: 591-8. doi: 10.2337/dc16-1875.

35. Thomas, M.C.; Woodward, M.; Neal, B.; Li, Q.; Pickering, R.; Marre, M.; Williams, B.; Perkovic, V.; Cooper, M.E.; Zoungas, S.; Chalmers, J.; Hillis, G.S.; ADVANCE Collaborative Group. Relationship between levels of advanced glycation end products and their soluble receptor and adverse outcomes in adults with type 2 diabetes. *Diabetes Care* 2015; 38: 1891-7. doi: 10.2337/dc15-0925.

36. Fishman, S.L.; Sonmez, H.; Basman, C.; Singh, V.; Foreskky, L. The role of advanced glycation end-products in the development of coronary artery disease in patients with and without diabetes mellitus: a review. *Mol Med* 2018; 24: 59. doi: 10.1186/s10020-018-0060-3.

37. Jiménez, I.U.; Díaz-Díaz, E.; Castro, J.S.; Ramos, J.P.; León, M.C.; Alvarado Ríos, J.A.; Auriostigue Bautista, J.C.; Correa-Rotter, R.; Aguilar-Salinas, C.A.; Larrea, C. Circulating concentrations of advanced glycation end products; its association with the development of diabetes mellitus. *Arch Med Res* 2017; 48; 360-9. doi: 10.1016/j.arcmed.2017.07.001

38. Wautier, M.P.; Massin, P.; Guillausseau, P.J.; Huijberts, M.; Levy, B.; Boulanger, E.; Laloi-Michelin, M.; Wautier, J.L. N(carboxymethyl)lysine as a Biomarker for Microvascular Complications in Type 2 Diabetic Patients. *Diabetes Metab* 2003; 29: 44-52. doi:10.1016/S1262-3636(07)70006-x.

39. Boehm B.O.; Schilling, S.; Rosinger, S.; Lang, G.E.; Lang, G.K.; Kientsch-Engel, R.; Stahl, P. elevated serum levels of n(epsilon)-carboxymethyl-lysine, an advanced glycation end product, are associated with proliferative diabetic retinopathy and macular oedema. *Diabetologia* 2004; 47; 1376-9. doi: 10.1007/s00125-004-1455-y.

40. Fosmark, D.S., Torjesen, P.A., Kilhovd, B.K., Berg, T.J., Sandvik, L., Hanssen, K.F., Agardh, C.D., Agardh, E. Increased serum levels of the specific advanced glycation end product methylglyoxal-derived hydroimidazolone are associated with retinopathy in patients with type 2 diabetes mellitus. *Metabolism* 2006; 55; 232-6. doi: 10.1016/j.metabol.2005.08.017.
41. Xu, J.; Chen, L.J.; Yu, J.; Wang, H.J.; Zhang, F.; Liu, Q.; Wu, J. Involvement of Advanced Glycation End Products in the Pathogenesis of Diabetic Retinopathy. *Cell Physiol Biochem* 2018; 48; 705-17. doi: 10.1159/000491897.

42. Shimoike, T.; Inoguchi, T.; Umeda, F.; Nawata, H.; Kawano, K.; Ochi, H. The Meaning of Serum Levels of Advanced Glycosylation End Products in Diabetic Nephropathy. *Metabolism* 2000; 49; 1030-5. doi: 10.1053/meta.2000.7738.

43. Prevost, G.; Fajardy, I.; Besmond, C.; Balkau, B.; Tichet, J.; Fontaine, P.; Danze, P.M.; Marre, M.; Genediab and D.E.S.I.R studies. Polymorphisms of the receptor of advanced glycation end products (rage) and the development of nephropathy in type 1 diabetic patients. *Diabetes Metab* 2005; 31; 35-9. doi: 10.1016/s1262-3636(07)70164-7.

44. Bucala, R.; Makita, Z.; Vega, G.; Grundy, S.; Koschinsky, T.; Cerami, A.; Vlassara, H. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. *Proc Natl Acad Sci U S A* 1994; 9; 9441-5. doi: 10.1073/pnas.91.20.9441.

45. Meerwaldt, R.; Links, T.; Zeebregts, C.; Tio, R.; Hillebrands, J.L.; Smit, A. The clinical relevance of assessing advanced glycation endproducts accumulation in diabetes. *Cardiovasc Diabetol* 2008; 7; 29. doi: 10.1186/1475-2840-7-29.

46. Gawandi, S.; Gangawane, S.; Chakrabarti, A.; Kedare, S.; Bantwal, K.; Wadhe, V.; Kulkarni, A.; Kulkarni, S.; Rajan, M.G.R. A Study of microalbuminuria (MAU) and advanced glycation end products (AGEs) levels in diabetic and hypertensive subjects. *Indian J Clin Biochem* 2018; 33; 81-5. doi: 10.1007/s12291-017-0638-5.

47. Singh, R.; Barden, A.; Mori, T.; Belin, L. Advanced glycation end-products: a review. *Diabetologia* 2001; 44; 129-46. doi: 10.1007/s001250051559.

48. Brownlee, M. The pathological implications of protein glycation. *Clin Invest Med* 1995; 18; 275-81.

49. Sell, D.R.; Monnier, V.M. Molecular basis of arterial stiffening: role of glycation - a mini-review. *Gerontology* 2012; 58; 227-37. doi: 10.1159/000334668.

50. Kilhovd, B.K.; Berg, T.J.; Birkeland, K.I.; Thorsby, P.; Hanssen, K.F. Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease. *Diabetes Care* 1999; 22; 1543-8. doi: 10.2337/diacare.22.9.1543.

51. Koska, J.; Sarem, A.; Howell, S.; Bahn, G.; De Courten, B.; Ginsberg, H.; Beisswenger, P.J.; Reaven, P.D.; VADT Investigators. Advanced glycation end products; oxidation products; and incident cardiovascular events in patients with type 2 diabetes. *Diabetes Care* 2018; 41; 570-6. doi: 10.2337/dc17-1740.

52. Yozgatli, K.; Lefrandt, J.D.; Noordzij, M.J.; Oomen, P.H.N.; Brouwer, T.; Jager, J.; Castro-Cabezas, M.; Smit AJ. Accumulation of advanced glycation end products is associated with macrovascular events and glycaemic control with microvascular complications in type 2 diabetes mellitus. *Diabet Med* 2018; Online ahead of print; doi: 10.1111/dme.13651.

53. Kim, H.S.; Chung, W.; Kim, A.J.; Ro, H.; Chang, J.H.; Lee, H.H.; Jung, J.Y. Circulating levels of soluble receptor for advanced glycation end product are inversely associated with vascular calcification in patients on haemodialysis independent of S100A12 (EN-RAGE) levels. *Nephrology (Carlton)* 2013; 18; 777-82. doi: 10.1007/s11255-011-0007-x.

54. Guerin-Dubourg, A.; Cournot, M.; Planesse, C.; Debussche, X.; Meilliac, O.; Rondeau, P.; Bourdon, E. Association between fluorescent advanced glycation end-products and vascular complications in type 2 diabetic patients. *Biomed Res Int* 2017; 2017; 7989180. doi: 10.1155/2017/7989180.

55. Hangai, M.; Takebe, N.; Homma, H.; Sasaki, A.; Chida, A.; Nakano, R.; Togashi, H.; Nakagawa, R.; Oda, T.; Matsu, M.; Yashiro, S.; Nagasawa, K.; Kajiwara, T.; Takahashi, K.; Takahashi, Y.; Satoh, J.; Ishigaki, Y. Association of advanced glycation end products with coronary artery calcification in japanese subjects with type 2 diabetes as assessed by skin autofluorescence. *J Atheroscler Thromb* 2016; 23; 1178-87. doi: 10.5551/jat.30155.

56. Simm, A.; Wagner, J.; Gursinsky, T.; Nass, N.; Friedrich, I.; Schinzel, R.; Czeslik, E.; Silber, R.E.; Scheubel, R.J. Advanced glycation endproducts: a biomarker for age as an outcome predictor after cardiac surgery? *Exp Gerontol* 2007; 42; 668-75. doi: 10.1016/j.exger.2007.03.006.

57. Okura, T.; Ueta, E.; Nakamura, R.; Fujiyoka, Y.; Sumi, K.; Matsumoto, K.; Shoji, K.; Matsuzawa, K.; Izawa, S.; Nomi, Y.; Mihara, H.; Otsuka, Y.; Kato, M.; Taniguchi, S.I.; Yamamoto, K. High serum advanced glycation end products are associated with decreased insulin secretion in patients with type 2 diabetes: A Brief Report. *J Diabetes Res* 2017; 2017; 5139750. doi: 10.1155/2017/5139750.
58. Assiri, A.M.A.; Kamel, H.F.M.; ALrefai, AA. Critical Appraisal of Advanced Glycation End Products (AGEs) and Circulating Soluble Receptors for Advanced Glycation End Products (sRAGE) as a Predictive Biomarkers for Cardiovascular Disease in Hemodialysis Patients. *Med Sci (Basel)* 2018; 6; 38. doi: 10.3390/medsci6020038.

59. van Eupen, M.G.; Schram, M.T.; Colhoun, H.M.; Scheijen, J.L.; Stehouwer, C.D.; Schalkwijk, C.G. Plasma levels of advanced glycation end products are associated with type 1 diabetes and coronary artery calcification. *Cardiovasc Diabetol* 2013; 12; 149. doi: 10.1186/1475-2840-12-149.

60. Saleh, J. Glycated hemoglobin and its spinoffs: Cardiovascular disease markers or risk factors? *World J Cardiol* 2015; 7; 449-53. doi: 10.4330/wjc.v7.i8.449.

61. Jung, J.G.; Wu, L.T.; Kim, J.S.; Kim, E.D.; Yoon, S.J. Relationship between Smoking and Abdominal Aorta Calcification on Computed Tomography. *Korean J Fam Med* 2019; 40; 248-53. doi: 10.4082/kjfm.17.0098.

62. Kauppila, L.; Polak, J.F.; Cupples, L.A.; Hannan, M.T.; Kiel, D.P.; Wilson, P.W. New indices to classify location; severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study. *Atherosclerosis* 1997; 132; 245-250. doi: 10.1016/s0021-9150(97)00106-8

63. Allison, M.A.; Criqui, M.H.; Wright, C.M. Patterns and risk factors for systemic calcified atherosclerosis. *Arterioscler Thromb Vasc Biol* 2004; 24; 331-336. doi: 10.1161/01.ATV.0000110786.02097.0c.

64. Nguyen, P.T.H.; Coche, E; Goffin E; et al. Prevalence and determinants of coronary artery calcification assessed by chest CT in renal transplant recipients. *Am J Nephrol* 2007; 27; 329-35. doi: 10.1159/000102978.

65. Quispe, R.; Martin, S.S.; Jones, S.R. Triglycerides to high-density lipoprotein-cholesterol ratio; glycemic control and cardiovascular risk in obese patients with type 2 diabetes. *Curr Opin Endocrinol Diabetes Obes* 2016; 23; 150-6. doi: 10.1097/MED.0000000000000241.

66. Nordestgaard, B.G.; Benn, M.; Schnohr, P.; Tybjaerg-Hansen, A. Non-fasting triglycerides and risk of myocardial infarction and death among women and men. *Ugeskr Laeger* 2007; 169; 3865-8. doi: 10.1177/204748731435681.

67. Sarwar, N.; Danesh, J.; Eiriksdottir, G.; Sigurdsson, G.; Wareham, N.; Bingham, S.; Boekholdt, S.M.; Khaw, K.T.; Gudnason, V. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. *Circulation* 2007; 115; 450-8. doi: 10.1161/CIRCULATIONAHA.106.637793.

68. Nichols, G.A.; Philip, S.; Reynolds, K.; Granowitz, C.B.; Fazio, S. Increased cardiovascular risk in Hypertriglycerideremic Patients With Statin-Controlled LDL Cholesterol. *J Clin Endocrinol Metab.* 2018; 103; 3019-27. doi: 10.1210/jc.2018-00470.

69. Leopold, J.A. Vascular calcification: Mechanisms of vascular smooth muscle cell calcification. Trends Cardiovasc Med. 2015; 25; 267-74. doi: 10.1016/j.tcm.2014.10.021.

70. Brownlee, M. Biochemistry and molecular cell biology of diabetic complications. *Nature* 2001; 414; 813-20. doi: 10.1038/414813a

71. Yamagishi, S.I.; Matsu, T. Therapeutic Potential of DNA-aptamers Raised Against AGE-RAGE Axis in Diabetes-related Complications. *Curr Pharm Des* 2018; 24; 2802-2809. doi: 10.2174/138161282466180829110124.

72. Sanchis, P.; Rivera, R.; Berga, F.; Fortuny, R.; Adrover, M.; Costa-Bauza, A.; Grases, F.; Masmiquel, L. Phytate Decreases Formation of Advanced Glycation End-Products in Patients with Type II Diabetes: Randomized Crossover Trial. *Sci Rep* 2018; 8; 9619. doi: 10.1038/s41598-018-27853-9.

73. Fernández-Palomeque, C.; Grau, A.; Perelló, J.; Sanchis, P.; Isern, B.; Prieto, R.M.; Costa-Bauzá, A.; Caldés, O.J; Bonnin, O.; Garcia-Raja, A.; Bethencourt, A.; Grases, F. Relationship between Urinary Level of Phytate and Valvular Calcification in an Elderly Population: A Cross-Sectional Study. *PLoS One* 2015; 10; e0136560. doi: 10.1371/journal.pone.0136560.

74. Sanchis, P.; Buades, J.M.; Berga, F.; Gelabert, M.M.; Molina, M.; Íñigo, M.V.; García, S.; Gonzalez, J; Bernabeu. M.R.; Costa-Bauzá, A.; Grases, F. Protective effect of myo-inositol hexaphosphate (phytate) on abdominal aortic calcification in patients with chronic kidney disease. *J Ren Nutr* 2016; 26; 226-36. doi: 10.1053/j.jrn.2016.01.010.

75. Grases, F.; Sanchis, P.; Perello, J; Isern, B; Prieto, R.M.; Fernandez-Palomeque, C.; Saus, C. Phytate reduces age-related cardiovascular calcification. *Front Biosci* 2008; 13; 7115-22. doi: 10.2741/3214.

76. Bekki, M.; Tahara, N.; Tahara, A.; Igata, S.; Honda, A; Sugiyama, Y.; Nakamura, T.; Sun, J.; Kumashiro, Y.; Matsui, T.; Fukumoto, Y.; Yamagishi, S.I. Switching dipeptidyl peptidase-4 inhibitors to tofogliflozin; a selective inhibitor of sodium-glucose cotransporter 2 improve arterial stiffness evaluated by cardiac-ankle
vascular index in patients with type 2 diabetes: a pilot study. *Curr Vasc Pharmacol* 2019; 17: 411-20. doi: 10.2174/1570161116666180515154555.

77. Vlassara, H. Advanced glycation in health and disease: role of the modern environment. *Ann N Y Acad Sci* 2005; 1043; 452-60. doi: 10.1196/annals.1333.051.

78. Yamagishi, S.; Matsui, T. Pathologic role of dietary advanced glycation end products in cardiometabolic disorders; and therapeutic intervention. *Nutrition* 2016; 32; 157-65. doi: 10.1016/j.nut.2015.08.001

79. Wilson PW; Kauppila LI; O'Donnell CJ; Kiel DP; Hannan M; Polak JM; Cupples LA. Abdominal aortic calcific deposits are an important predictor of vascular morbidity and mortality. *Circulation* 2001; 103; 1529-34. doi: 10.1161/01.cir.103.11.1529.